Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (5131)	2/25/2019 11:38:52 AM
From: richardred	Respond to of 7260

Roche Bids $4.8 Billion for U.S.-Based Gene Therapy Specialist Spark fortune.com

To: richardred who wrote (5131)

3/27/2019 12:09:41 PM

From: richardred

Read Replies (1) | Respond to of 7260

ENZ-Speculation

Enzo Biochem Shares Up After Roumell Calls for Monetization Efforts
BY Dow Jones & Company, Inc.
— 7:51 PM ET 03/26/2019
Shares of Enzo Biochem Inc. rose 9.8% to $2.80 after hours after Roumell Asset Management LLC reported a 4.1% stake and called for it to look into "monetization opportunities." Roumell said "we believe the time has come for the board to recognize that the company is too small to be successful on its own." It asked whether management has "clearly articulated" to the board "what the company is worth today in a sale," whole or in parts.

Write to Josh Beckerman at josh.beckerman@wsj.com

  (END) Dow Jones Newswires   03-26-19 1951ET   Copyright (c) 2019 Dow Jones & Company, Inc.

To: richardred who wrote (5034) 2/12/2019 11:02:46 AM
From: richardred Read Replies (2) of 5150

ENZ-Speculation- David wins 21 million from Goliath Roche. More to come?

Roche to Pay Enzo $21 Million to Settle Patent Infringement Suit
Roche Holdings Ltd. (RHHBY) will pay $21 million patent infringement settlement to Enzo Biochem Inc., Enzo said in a filing with the U.S. Securities and Exchange Commission Monday.

In its 2012 lawsuit, Enzo, a biotechnology company, said that Roche sold certain nucleic acid products in the U.S. used for genetic testing for diseases. The settlement, agreed on by the companies last week, involves several of Roche Holdings' subsidiaries, Roche Diagnostics GmbH and Roche Molecular Systems that make medical equipment.

Enzo said in the filing that this settlement doesn't affect its civil action for patent infringement against Roche in the U.S. District Court for the State of Delaware.

Representatives from Enzo and Roche couldn't be immediately reached for comment.

ih.advfn.com